ALK has decent growth forecast in sight
Danish bank Sydbank deems that allergy company ALK's tablet sales are well underway, but will keep eye on Covid-19 consequences in Wednesday's interim report from the company.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Danish allergy company ALK's Q4 report will probably show growing tables sales with emphasis on the firm's 2021 guidance and expectations for future growth.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck plans for carbon neutrality by 2050
For subscribers
